سعر سالسيفوزون 1.5جم فيال عضل/وريد 2024

Sulcefozone 1.5 gm i.m. / i.v. vial: Egyptian parenteral antibiotic (third-generation cephalosporin cefoperazone with the beta-lactamase inhibitor sulbactam), 1.5 g powder vial for IM/IV injection.

• Respiratory tract infections (upper and lower) caused by susceptible organismsPfizer Labeling (labeling.pfizer.com)
• Urinary tract infections (upper and lower) caused by susceptible organismsPfizer Labeling (labeling.pfizer.com)
• Peritonitis, cholecystitis, cholangitis and other intra-abdominal infections caused by susceptible organismsPfizer Labeling (labeling.pfizer.com)

• Very common: laboratory haematological changes (neutropenia, leucopenia, positive Coombs, decreased haemoglobin/haematocrit, thrombocytopenia) and raised ALT/AST/alkaline phosphatase. Common: coagulopathy, eosinophilia, diarrhoea, nausea, vomiting, raised bilirubin. Uncommon: headache, pruritus, urticaria, infusion-site phlebitis, injection-site pain, pyrexia, chills.International label, same formulation · Pfizer Labeling (labeling.pfizer.com)

• Hypersensitivity to sulbactam, cefoperazone, other beta-lactams or any excipient.International label, same formulation · Pfizer Labeling (labeling.pfizer.com)

• Serious, occasionally fatal anaphylactic reactions; enquire about previous hypersensitivity to cephalosporins, penicillins or other drugs before treatment.International label, same formulation · Pfizer Labeling (labeling.pfizer.com)
• Severe skin reactions (TEN, Stevens-Johnson syndrome, exfoliative dermatitis) have been reported; discontinue if they occur.International label, same formulation · Pfizer Labeling (labeling.pfizer.com)
• Haemorrhage (sometimes fatal) and vitamin K deficiency/coagulopathy reported; monitor prothrombin time/INR in at-risk patients and those on oral anticoagulants and give vitamin K as indicated.International label, same formulation · Pfizer Labeling (labeling.pfizer.com)

• Alcohol (including ethanol-containing feeding solutions)Disulfiram-like reaction (flushing, sweating, headache, tachycardia) reported when alcohol taken during and up to the fifth day after cefoperazone.Pfizer Labeling (labeling.pfizer.com)
• AminoglycosidesIf used together, monitor renal function during therapy; do not mix in the same solution (physical incompatibility per label section 6.2).Pfizer Labeling (labeling.pfizer.com)
• Urine glucose tests (Benedict's/Fehling's)False-positive urine glucose reaction may occur.Pfizer Labeling (labeling.pfizer.com)

• No impaired fertility or teratogenicity in rat studies at up to 10 times the human dose; both drugs cross the placenta; no adequate studies in pregnant women — use only if clearly needed.International label, same formulation · Pfizer Labeling (labeling.pfizer.com)
• Only small quantities of sulbactam and cefoperazone pass into breast milk; use with caution in nursing mothers.International label, same formulation · Pfizer Labeling (labeling.pfizer.com)

• Cefoperazone: Third-generation cephalosporin that acts against sensitive organisms during active multiplication by inhibiting cell-wall mucopeptide biosynthesis (Sulperazon LPD).
• Sulbactam: Irreversible inhibitor of most important beta-lactamases; little useful antibacterial activity alone except against Neisseriaceae and Acinetobacter (Sulperazon LPD).